Skip to main content

Advertisement

SpringerLink
Log in

Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Despite their efficacy in the treatment of benign prostatic hyperplasia (BPH) the popularity of inhibitors of 5α-reductase (5ARI) is limited by their association with adverse sexual side effects. However, the real impact of 5ARI on sex hormones and sexual function is controversial. Aim: To investigate the role of 5ARI therapy on hormonal parameters and sexual function in men already complaining of sexual problems. Materials and methods: A consecutive series of 3837 men (mean age 63.5±12.8 yr) attending our outpatient clinic for sexual dysfunction was retrospectively studied. Several clinical, biochemical, and instrumental (penile color doppler ultrasound) factors were evaluated. Results: Among the patients studied, 78.7% reported erectile dysfunction, 51.1% hypoactive sexual desire (HSD), 86.7% perceived reduced sleep-related erections (PR-SRE) and 19.1 % premature ejaculation. The use of 5ARI was associated with an increased risk of HSD and PR-SR whereas no relationship was found with erectile dysfunction and ejaculation disturbances. Subjects using 5ARI also more frequently had gynecomastia along with reduced SHBG and higher calculated free testosterone levels. All these associations were confirmed in a case-control study comparing 5ARI users with age-body mass index-smoking status and total testosterone-matched controls. Conclusions: Our data indicates that use of 5ARI in men with sexual dysfunction does not significantly exacerbate pre-existing ejaculatory or erectile difficulties, but can further impair their sexual life by reducing sexual drive and spontaneous erection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010, 33: 475–88.

    Article  PubMed  CAS  Google Scholar 

  2. Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int 2011, 107: 876–80.

    Article  PubMed  Google Scholar 

  3. Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010, 28: 9–15.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of PC. N Engl J Med 2003, 349: 215–24.

    Article  PubMed  CAS  Google Scholar 

  5. Anitha B, Inamadar AC, Ragunatha S. Finasteride-its impact on sexual function and prostate cancer. J Cutan Aesthet Surg 2009, 2: 12–6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  6. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 2002, 2: 14.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Erdemir F, Harbin A, Hellstorm WJ. 5a reductase inhibitors and erectile dysfunction: The connection. J Sex Med 2008, 5: 2917–24.

    Article  PubMed  Google Scholar 

  8. Canguven O, Burnett AL. The effect of 5 alpha-reductase inhibitors on erectile function. J Androl 2008, 29: 514–23.

    Article  PubMed  CAS  Google Scholar 

  9. Gormley GJ, Stoner E, Bruskewitz RC, et al; Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia: The Finasteride study group. N Engl J Med 1992, 327: 1185–91

    Article  PubMed  CAS  Google Scholar 

  10. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996, 155: 1251–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  11. Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998, 34: 169–75.

    Article  PubMed  CAS  Google Scholar 

  12. Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the prostate cancer prevention trial. J Natl Cancer Inst 2007, 99: 1025–35.

    Article  PubMed  Google Scholar 

  13. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994, 43: 284–92.

    Article  PubMed  CAS  Google Scholar 

  14. Wessels H, Roy J, Bannow J, et al; PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo treated men with benign prostatic hyperplasia. Urology 2003, 61: 579–84.

    Article  Google Scholar 

  15. Tosti A, Pazzaglia M, Soli M, et al. Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol 2004, 140: 857–8.

    Article  PubMed  CAS  Google Scholar 

  16. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 2010, 146: 1141–50.

    Article  PubMed  Google Scholar 

  17. Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon? J Sex Med 2007, 4: 1708–12.

    Article  PubMed  Google Scholar 

  18. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004, 63: 709–15.

    Article  PubMed  Google Scholar 

  19. Andriole GL, Kirby R. Safety and tolerability of the dual 5 alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003, 44: 82–8.

    Article  PubMed  CAS  Google Scholar 

  20. Goldstein I. An old problem with a new cause-5 alpha reductase inhibitors and persistent sexual dysfunction. J Sex Med 2011, 8: 1829–31.

    Article  PubMed  Google Scholar 

  21. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011, 8: 872–84.

    Article  PubMed  CAS  Google Scholar 

  22. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med 2011, 8: 1747–53.

    Article  PubMed  Google Scholar 

  23. Uygur MC, Arik AI, Altug U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids 1998, 63: 208–13.

    Article  PubMed  CAS  Google Scholar 

  24. Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007, 92: 1659–65.

    Article  PubMed  CAS  Google Scholar 

  25. Petrone L, Mannucci E, Corona G, et al. Structured interview on erectile dysfunction (SIEDY): a new, multi-dimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 2003, 15: 210–20.

    Article  PubMed  CAS  Google Scholar 

  26. Corona G, Jannini EA, Maggi M. Inventories for male and female sexual dysfunctions. Int J Impot Res 2006, 18: 236–50.

    Article  PubMed  CAS  Google Scholar 

  27. Corona G, Ricca V, Bandini E, et al. Association between psychiatric symptoms and erectile dysfunction. J Sex Med 2007, 5: 458–68.

    PubMed  Google Scholar 

  28. Corona G, Petrone L, Mannucci E, et al. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol 2004, 46: 615–22.

    Article  PubMed  CAS  Google Scholar 

  29. Corona G, Ricca V, Boddi V, et al. Autoeroticism, mental health, and organic disturbancies in patients with erectile dysfunction. J Sex Med 2010, 7: 182–91.

    Article  PubMed  Google Scholar 

  30. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84: 3666–72.

    Article  PubMed  CAS  Google Scholar 

  31. Corona G, Fagioli G, Mannucci E, et al. Penile doppler ultrasound in patients with erectile dysfunction (ED): role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med 2008, 5: 2623–34.

    Article  PubMed  Google Scholar 

  32. Seftel AD. Diagnosis of Erectile Dysfunction. In: Porst H, Buvat J, ed. Standard Practice in Sexual Medicine. Malden (USA): Blackwell Publishing. 2006, p 67.

    Google Scholar 

  33. Hatzichristou D, Rosen R, Derogatis L, et al. Clinical evaluation and symptom scales in men and women with sexual dysfunction. In: Adaikan G, Basson R, Becher E, et al. (eds). Sexual Medicine: sexual dysfunctions in men and women. The 3rd International Consultation on Sexual Medicine. Paris, France: Health Publication Ltd. 2010, pp. 229–80.

    Google Scholar 

  34. Andriole GL, Bostwick DG, Brawley OW, et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362: 1192–202.

    Article  PubMed  CAS  Google Scholar 

  35. Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med 2011, 8: 3066–74.

    Article  PubMed  CAS  Google Scholar 

  36. Corona G, Rastrelli G, Balercia G, et al. Perceived reduced sleep-related erections in subjects with erectile dysfunction: psychobiological correlates. J Sex Med 2011, 8: 1780–8.

    Article  PubMed  CAS  Google Scholar 

  37. Jannini EA, Granata AM, Hatzimouratidis K, Goldstein I. Use and abuse of Rigiscan in the diagnosis of erectile dysfunction. J Sex Med 2009, 6: 1820–9.

    Article  PubMed  Google Scholar 

  38. Cunningham GR, Hirshkowitz M. Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab 1995, 80: 1934–40.

    PubMed  CAS  Google Scholar 

  39. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. How to recognize late onset hypogonadism in men with sexual dysfunction. Asian J Androl 2012, 14: 251–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  40. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010, 7: 46–56.

    Article  PubMed  CAS  Google Scholar 

  41. Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol 2012, 2012: 530121.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sexual Medicine and Andrology Unit, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy

    G. Corona, G. Rastrelli, E. Maseroli & M. Maggi

  2. Endocrinology Unit, Azienda USL di Bologna, Medical Department, Maggiore-Bellaria Hospital, Bologna, Italy

    G. Corona & A. Sforza

  3. Endocrinology Unit, Polytechnic University of Marche, Ancona, Italy

    G. Balercia

  4. Endocrinology Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy

    G. Forti

  5. Diabetes Section Geriatric Unit, Department of Critical Care, University of Florence, Florence, Italy

    E. Mannucci

Authors
  1. G. Corona
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Rastrelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Maseroli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Balercia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Sforza
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Forti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Mannucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Maggi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Maggi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corona, G., Rastrelli, G., Maseroli, E. et al. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. J Endocrinol Invest 35, 915–920 (2012). https://doi.org/10.3275/8510

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/8510

Key-words

Search

Navigation